Stockscreener 앱 받기
6.245
1.42%
-0.09
시간 외 거래:
6.25
0.005
+0.08%
전일 마감가:
$6.335
열려 있는:
$6.3701
하루 거래량:
9,188
Relative Volume:
1.00
시가총액:
$57.96M
수익:
$70,100
순이익/손실:
$-9.67M
주가수익비율:
-5.4252
EPS:
-1.1511
순현금흐름:
$-7.09M
1주 성능:
-2.95%
1개월 성능:
-17.07%
6개월 성능:
-13.26%
1년 성능:
-57.13%
1일 변동 폭
$6.12
$6.655
1주일 범위
$6.11
$6.985
52주 변동 폭
$4.35
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
명칭
Exozymes Inc
전화
(626) - 415 - 1488
주소
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
6.245 | 57.96M | 70,100 | -9.67M | -7.09M | -1.1511 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exozymes Inc 주식(EXOZ)의 최신 뉴스
eXoZymes, Inc. (EXOZ) stock price, news, quote and history - uk.finance.yahoo.com
Form 8K eXoZymes Inc For: 18 September By Investing.com - Investing.com Nigeria
Exozymes sets date for 2026 annual meeting and announces record date - Investing.com
EXOZ: eXoZymes Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Exozymes (EXOZ) grants VP 45,000 stock options - Stock Titan
EXOZ 424B FilingseXoZymes Inc. SEC 424B - Stock Titan
EXOZ 8-K FilingseXoZymes Inc. SEC 8-K - Stock Titan
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
eXoZymes (EXOZ) Stock: Curia Deal Moves NCT Toward Commercial Production - Blockonomi
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com Nigeria
exozymes partners with Curia for NCT manufacturing scale-up - Investing.com
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - The Joplin Globe
A 3,000-employee manufacturer will help eXoZymes move a product toward larger-scale production. - Stock Titan
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com South Africa
Exozymes CEO Michael Heltzen buys $6,405 in company stock - Investing.com
Exozymes (EXOZ) CEO adds stock with August buys and grant - stocktitan.net
eXoZymes Inc. (EXOZ) Edges Lower, Holding Support at $6.13 After 0.77% DipNAAIM Exposure - dars.gov.et
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - Barchart.com
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - Barchart.com
eXoZymes Inc. (EXOZ) Holds Near $7.17 as Shares Trade Within Established RangePut Dominated - vinanet.vn
Primer: eXoZymes (EXOZ US)Aug 2026 - Smartkarma
Exozymes (EXOZ) CSO adds 32,964 shares from RSU vesting - Stock Titan
EXoZymes Inc (EXOZ) (Q2 2026) Earnings Call Highlights: Strategic Pivot and 10x Productivity ... - Yahoo Finance
eXoZymes (EXOZ): Ends Up by 10.00% at $7.04; Trading Range: the Near-Term Reference Band Stretches From $6.69 to $7.39 in the Available RecordKey Reversal Day - vinanet.vn
eXoZymes Q2FY26 Results: Net loss widens to $2.88M, raises $6M - scanx.trade
eXoZymes Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance - Investing.com
EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization - TradingView
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - The Batesville Daily Guard
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com Canada
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - ACCESS Newswire
EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - marketscreener.com
Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisely? - webull.com
eXoZymes Inc. (EXOZ) Drops 3% to $5.82, Pressuring Key Support at $5.53Narrow Range Breakout - vinanet.vn
MDB Capital Holdings (MDBH) records $16.1M H1 2026 loss and $33.1M eXoZymes stake - Stock Titan
EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
EXOZ 10-Q FilingseXoZymes Inc. SEC 10-Q - Stock Titan
eXoZymes Inc (EXOZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
eXoZymes Q2 Results: Update call scheduled for August 20 - scanx.trade
eXoZymes CEO to Lead Q2 Results Webinar With Q&A Aug. 20 - Stock Titan
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 - ACCESS Newswire
eXoZymes Inc. (EXOZ) Climbs 3.92% to $5.3 as Biotech Stock Approaches Key ResistancePut Spread Alert - dars.gov.et
eXoZymes Inc (EXOZ) Stock News Today - TradingKey
eXoZymes (EXOZ) Slides 5.15% to $4.6 as Biotech Selling Pressure IntensifiesBuyback Factor - careplusvn.com
eXoZymes Inc. (EXOZ) Slips 1.1% as Shares Test Support Near $4.27Risk Reversal - vinanet.vn
eXoZymes Inc (EXOZ) Income Statement - TradingKey
Exozymes Inc (EXOZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):